Trial · NCT00599339
Results by group198
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 198
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III at Visit 7 (Month 33) | Neupro Monotherapy (>= 3 Months) | -2.5 | Standard Deviation 14.7 | units on a scale | |
| Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III at Visit 7 (Month 33) | Neupro Monotherapy (< 3 Months) | -2.5 | Standard Deviation 10.3 | units on a scale | |
| Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III at Visit 7 (Month 33) | Other Dopamine Agonist (>= 3 Months) | -2.2 | Standard Deviation 11.1 | units on a scale | |
| Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III at Visit 7 (Month 33) | Other Dopamine Agonist (< 3 Months) | -5.6 | Standard Deviation 16.9 | units on a scale | |
| Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III at Visit 7 (Month 33) | L-Dopa Monotherapy (>= 3 Months) | 0.2 | Standard Deviation 13.2 | units on a scale | |
| Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III at Visit 7 (Month 33) | L-Dopa Monotherapy (< 3 Months) | 0.0 | Standard Deviation 12.2 | units on a scale | |
| Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III at Visit 7 (Month 33) | Multiple Dopamine Agonists (>= 3 Months) | -1.2 | Standard Deviation 13.8 | units on a scale | |
| Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III at Visit 7 (Month 33) | Multiple Dopamine Agonists (< 3 Months) | 3.5 | Standard Deviation 6.4 | units on a scale | |
| Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III at Visit 7 (Month 33) | Neupro + L-Dopa (>= 3 Months) | -1.2 | Standard Deviation 14.2 | units on a scale | |
| Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III at Visit 7 (Month 33) | Neupro + L-Dopa (< 3 Months) | -1.5 | Standard Deviation 17.5 | units on a scale | |
| Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III at Visit 7 (Month 33) | Other Dopamine Agonist + L-Dopa (>= 3 Months) | -2.5 | Standard Deviation 13.9 | units on a scale | |
| Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III at Visit 7 (Month 33) | Other Dopamine Agonist + L-Dopa (< 3 Months) | 8.6 | Standard Deviation 13.5 | units on a scale | |
| Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III at Visit 7 (Month 33) | Multiple Dopamine Agonists + L-Dopa (>= 3 Months) | 1.5 | Standard Deviation 14.7 | units on a scale | |
| Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III at Visit 7 (Month 33) | Multiple Dopamine Agonists + L-Dopa (< 3 Months) | 20.0 | Standard Deviation 29.7 | units on a scale | |
| Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III at Visit 7 (Month 33) | Not Treated (>= 3 Months) | -3.2 | Standard Deviation 10.8 | units on a scale | |
| Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III at Visit 7 (Month 33) | Not Treated (< 3 Months) | 4.1 | Standard Deviation 15.0 | units on a scale | |
| Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Question 32 of Part IV at Visit 7 (Month 33) | Neupro Monotherapy (>= 3 Months) | -0.1 | Standard Deviation 0.7 | units on a scale | |
| Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Question 32 of Part IV at Visit 7 (Month 33) | Neupro Monotherapy (< 3 Months) | -0.2 | Standard Deviation 0.6 | units on a scale | |
| Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Question 32 of Part IV at Visit 7 (Month 33) | Other Dopamine Agonist (>= 3 Months) | -0.1 | Standard Deviation 0.5 | units on a scale | |
| Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Question 32 of Part IV at Visit 7 (Month 33) | Other Dopamine Agonist (< 3 Months) | 0.0 | Standard Deviation 0.8 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00599339/results